In this update, we revisit LIDDS and take a deeper look at the company’s new vision and strategy, and NanoZolid®’s potential. We argue that the platform and the new focus area of immuno-oncology present a large opportunity and that the management has the capabilities and motivation to take advantage of it. We analyse the clinical data, the competition, the industry dynamics and present an updated valuation with a new target price.